Growth Hormone Deficiency Market Research Report: Information By Brand (Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope), By Application (Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small For Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, and Prader Willi Syndrome), By Route of Administration (Subcutaneous, Intramuscular, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forec

Global Growth Hormone Deficiency Market Overview

The Growth Hormone Deficiency Market Size was valued at USD 3.5 Billion in 202 and is projected to grow from USD 3.7 Billion in 2023 to USD 6.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.50% during the forecast period (2023 - 2032). An increase in cases of pituitary malfunction, the creation of recombinant human growth hormone therapies, and a rise in the use of human growth hormones outside of recommended dosages, are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Growth Hormone Deficiency Market Trends

• Rise in concern about passenger safety is driving the market growth

Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is crucial for human development because it promotes human cell growth, division, and regeneration. Insufficiency of growth hormone (GH) in humans is caused by insufficient hGH synthesis by the pituitary gland. To remedy this human deficiency, recombinant human growth hormone is subcutaneously administered. Genetic disorders including Prader-Willi syndrome and Turner syndrome, which can delay puberty and cause shorter-than-average height, can also cause growth hormone insufficiency in humans. According to data from the American Academy of Paediatrics, growth hormone deficiency in humans is a rare condition that affects less than one in 3,000 to one in 10,000 children in the U.S. Currently, hGH is extensively abused by bodybuilders, athletes, and senior citizens as an anabolic performance enhancer and anti-aging drug.

The discovery of novel growth hormone therapies is expected to be the main driver of the market for human growth hormones, along with a robust product pipeline. For instance, in September 2018, Novo Nordisk released findings from the Phase II clinical trial of Somapacitan, an investigational GH drug suggested for the treatment of paediatric growth hormone deficiency. Additionally, TransCon hGH Phase III clinical study results were made public by Ascendis Pharma A/S in May 2019. The goal of this medicine is to treat paediatric growth hormone deficiency. Similar to this, other significant companies, including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences, are actively involved in R&D activities for the development of cutting-edge HGH medications.

Campaigns made by several public and commercial groups to increase awareness of GH deficiencies and treatments for human growth hormone are also projected to have a significant impact on the market. The International Coalition of Organisations Supporting Endocrine Patients (ICOSEP), a non-profit organisation based in the United States, observes International Children's Growth Awareness Day every year to promote awareness of the value of early detection and treatment of growth hormone disorders in people, particularly children.

A growth hormone with fewer side effects that will be used as a long-term therapy is also being developed by a number of companies. The market's growth is related to the escalation of diseases brought on by the lack of this hormone. Governments and other for-profit entities continuously work to spread awareness about growth hormone deficiency and high productivity. The demand for human growth hormone drugs will rise due to other variables such increased treatment awareness and an increase in the prevalence of numerous health problems, including neuropsychiatric diseases, which will foster market expansion. The quick creation of novel compounds is anticipated to lead to an increase in the demand for human growth hormones. Thus, driving the Growth Hormone Deficiency market revenue.

Growth Hormone Deficiency Market Segment Insights

Growth Hormone Deficiency Brand Insights

The market segments of Growth Hormone Deficiency, based on brand, includes norditropin, genotropin, humatrope, saizen, and omnitrope. Norditropin segment dominated the  market in 2022. It has maintained that position for years, and the evaluation period suggests that growth will continue at a rapid pace. Norditropin HGH is one of Novo Nordisk's most popular prefilled and premixed products of human growth hormone.

Growth Hormone Deficiency Application Insights

The Growth Hormone Deficiency market segmentation, based on application, includes pediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, and prader willi syndrome. Pediatric growth hormone deficiency segment dominated the market of Growth Hormone Deficiency in 2022. This is attributable to increased public awareness of paediatric growth hormone insufficiency early detection and therapy as well as the launch of new drugs. For instance, Ascendis Pharma A/S received Orphan Designation from the European Commission (EC) for TransCon hGH in October 2018. It is advised to treat paediatric GH deficiency with this human investigational long-acting GH drug.

Growth Hormone Deficiency Route of Administration Insights

The market segmentation of Growth Hormone Deficiency, based on route of administration, includes subcutaneous, intramuscular, and intravenous. Subcutaneous segment dominated the market of Growth Hormone Deficiency in 2022. This is because the hormone, after being supplied subcutaneously, absorbs well in cells, which is advantageous for the patients.

Growth Hormone Deficiency Distribution Channel Insights

The market segmentation of Growth Hormone Deficiency, based on Distribution Channel, includes Hospital Pharmacies, Retail Pharmacies. Hospital Pharmacies segment dominated the  market in 2022. Because more people are aware of GH insufficiency in humans and how to treat it, there has been an increase in hospital visits, which is thought to be the cause of this high percentage.

Figure 1:  Growth Hormone Deficiency Market, by Distribution Channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Growth Hormone Deficiency Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Growth Hormone Deficiency Market dominated this market in 2022 (45.80%). This is due to elements like a favourable reimbursement environment, a developed healthcare infrastructure, considerable government initiatives, and rising public awareness of healthcare issues. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several major companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human GH medicines in the area. Further, the U.S. market of Growth Hormone Deficiency held the largest market share, and the Canada market of Growth Hormone Deficiency was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  GROWTH HORMONE DEFICIENCY MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Growth Hormone Deficiency market accounted for the healthy market share in 2022. The European market benefits from increased access to cutting-edge pharmaceuticals as a result of the presence of significant companies in the area. Further, the German market of Growth Hormone Deficiency held the largest market share, and the U.K market of Growth Hormone Deficiency was the fastest growing market in the European region

The Asia Pacific Growth Hormone Deficiency market is expected to register significant growth from 2023 to 2032. By obtaining clearance and launching innovative products, large market share in potential Asia Pacific nations like China and Japan is a goal for major firms. For instance, the phase III clinical trial of the pharmaceutical company Novo Nordisk A/S's HGH somapacitan, which is indicated for the treatment of adult growth hormone insufficiency, was started in Japan in March 2017. Moreover, China’s market of Growth Hormone Deficiency held the largest market share, and the Indian market of Growth Hormone Deficiency was the fastest growing market in the Asia-Pacific region.

Growth Hormone Deficiency Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Growth Hormone Deficiency, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Growth Hormone Deficiency Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Growth Hormone Deficiency Industry to benefit clients and increase the market sector. In recent years, the Growth Hormone Deficiency Industry has offered some of the most significant advantages to medicine. Major players in the market of Growth Hormone Deficiency, including Anhui Anke Biotechnology (Group) Co. Ltd., Pfizer Inc., Genetech Inc., Biopartners GmbH, Lifetech Labs, Zhongshan Hygene Biopharm Co. Ltd., Novo Nordisk A/S, Eli Lily and Company, and Ipsen S.A., are attempting to increase market demand by investing in research and development operations.

Novo Nordisk AS (Novo Nordisk), a part of Novo Holdings AS, is a healthcare company devoted to the development and production of cutting-edge biological medicines. It focuses on creating drugs to treat diabetes as well as other severe chronic conditions like haemophilia, HGH issues, rare blood and endocrine diseases, and obesity. The company's product line includes pre-filled insulin delivery systems, glucagon hypokit, cartridges, needles and vials as well as estradiol for hormone replacement, recombinant medicines for haemophilia, glucagon and oral diabetes treatments. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia. Denmark's Bagsvaerd serves as Novo Nordisk's corporate headquarters. In order to obtain the rights to MACRILEN in the US and Canada, Novo Nordisk and Strongbridge Biopharma entered into a contract in October 2018. Only one oral drug, MACRILEN (macimorelin), has FDA approval for use in adult growth hormone deficiency diagnosis.

Pfizer Inc. discovers, creates, manufactures, and markets biopharmaceuticals. The company sells products to treat a variety of illnesses, including as cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic pain disorders, as well as problems with women's health. Additionally, it provides pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), sterile injectable drugs, contract manufacturing services, and services. Pfizer sells its products through wholesalers, retailers, pharmacies, hospitals, private medical practises, clinics, and governmental organisations. Significant manufacturing facilities for it can be found in Singapore, India, China, Japan, Ireland, Italy, Belgium, and the US. The business sends its products to North and South America, Australia, Asia-Pacific, Europe, Africa, and the Middle East. Pfizer is based in New York in the United States. According to a press statement issued in February 2021 by The Pfizer and OPKO Health Inc., Somatrogon has been given the green light by the European Medicines Agency for the treatment of persons who do not make enough juvenile growth hormone.

Key Companies in the market of Growth Hormone Deficiency include

• Anhui Anke Biotechnology (Group) Co. Ltd.


• Pfizer Inc.


• Genetech Inc.


• Biopartners GmbH


• Lifetech Labs


• Zhongshan Hygene Biopharm Co. Ltd.


• Novo Nordisk A/S


• Eli Lily and Company


• Ipsen S.A.

Growth Hormone Deficiency Industry Developments

August 2021:In August 2021, the FDA approved the injectable SKYTROFA from Ascendis Pharma. The corporation will be able to make a sizable profit when this product is launched on the world market.

Growth Hormone Deficiency Market Segmentation

Growth Hormone Deficiency Brand Outlook

• Norditropin


• Genotropin


• Humatrope


• Saizen


• Omnitrope

Growth Hormone Deficiency Application Outlook

• Pediatric Growth Hormone Deficiency


• Idiopathic Short Stature


• Small For Gestational Age


• Turner Syndrome


• Adult Growth Hormone Deficiency


• Prader Willi Syndrome

Growth Hormone Deficiency Route of Administration Outlook

• Subcutaneous


• Intramuscular


• Intravenous

Growth Hormone Deficiency Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies

Growth Hormone Deficiency Regional Outlook

• North America


• US


• Canada


• Europe


• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

Report Attribute/Metric	Details
Market Size 2022	USD 3.5 Billion
Market Size 2023	USD 3.7 Billion
Market Size 2032	USD 6.2 Billion
Compound Annual Growth Rate (CAGR)	6.50% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Brand, Application, Route of Administration, Distribution Channel, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Anhui Anke Biotechnology (Group) Co. Ltd., Pfizer Inc., Genetech Inc., Biopartners GmbH, Lifetech Labs, Zhongshan Hygene Biopharm Co. Ltd., Novo Nordisk A/S, Eli Lily and Company, and Ipsen S.A.
Key Market Opportunities	Increasing elderly population
Key Market Dynamics	The development of recombinant human growth hormone medications, an increase in cases of pituitary dysfunction, and an increase in the use of human growth hormones outside of prescribed dosages

Frequently Asked Questions (FAQ) :